Read the full article on Biosimilar Development here
Chris Isler and Magnus Franzen, life science experts at PA Consulting Group are quoted in Biosimilar Development’s article looking at trends and challenges in the biosimilar industry and how it could “break from tradition” in the next few years.
Anna Rose asks: What new biosimilar trends should companies pay attention to in 2018? What impact do you feel these will have on the industry moving forward?
Chris and Magnus reply: "We’ve been closely watching the arrival of Indian biosimilar companies’ products in the U.S. Until now, we believed Indian companies would have a hard time competing in more mature markets like the EU and U.S. because of the lack of IP protection and regulatory rigor in the production. However, recent FDA approvals of manufacturing plants and approval of Biocon’s trastuzumab biosimilar may be the first steps to proving us wrong."
Anna Rose then asks: In what particular way(s) will biosimilar companies need to break from tradition in 2018?
Magnus and Chris reply: "Two ways companies are thinking differently about biosimilars and are trying to differentiate from the competition are in customer experience of the product and customer engagement. For instance, Biogen’s development of a device superior to Amgen’s Enbrel device is an example of how a company can differentiate with the experience of the product, while maintaining biosimilarity.
"When thinking about biosimilar customer engagement, we believe companies will have to develop their view of the role of channels — though this will of course be highly market-dependent. In the U.S., we’re watching the role of pharmacy benefit managers (PBMs). Similarly, in Europe, the central procurement teams of integrated wholesalers like McKesson-Celesio may come to push the market in certain directions.
"Some of the big players in the biosimilar space may not traditionally have had a strong channel focus, but will have to develop new capabilities to engage effectively with certain customer groups."